# Supplementary Information

**Figure S1.** Isolation scheme for **13** and **14**. Red highlights indicate antimalarial activity.



**Figure S2.** $^{1}$H NMR spectrum of **14** (500 MHz, $CDCl_3$).



**Figure S3.** $^{13}C$ NMR spectrum of **14** (125 MHz, $CDCl_3$).



**Figure S4.** COSY spectrum of **14** (500 MHz, $CDCl_3$).



**Figure S5.** HSQC spectrum of **14** (500 MHz, $CDCl_3$).



**Figure S6.** HMBC spectrum of **14** (500 MHz, $CDCl_3$).



**Figure S7.** ROESY spectrum of **14** (500 MHz, $CDCl_3$).



**Figure S8.** Isolation scheme for **15** and **16**. Red highlights indicate antimalarial activity.



**Figure S9.** $^{1}$H NMR spectrum of **15** (500 MHz, $CDCl_3$).



**Figure S10.** $^{13}C$ NMR spectrum of **15** (125 MHz, $CDCl_3$).



**Figure S11.** COSY spectrum of **15** (500 MHz, $CDCl_3$).



**Figure S12.** HSQC spectrum of **15** (500 MHz, $CDCl_3$).



**Figure S13.** HMBC spectrum of **15** (500 MHz, $CDCl_3$).



**Figure S14.** Expansion of ROESY spectrum of **15**, 0–5 ppm (600 MHz, $CDCl_3$).



**Figure S15.** $^{1}$H NMR spectrum of **16** (500 MHz, $CDCl_3$).



**Figure S16.** $^{13}C$ NMR spectrum of **16** (125 MHz, $CDCl_3$).



**Figure S17.** COSY spectrum of **16** (500 MHz, $CDCl_3$).



**Figure S18.** HSQC spectrum of **16** (500 MHz, $CDCl_3$).



**Figure S19.** HMBC spectrum of **16** (500 MHz, $CDCl_3$).



**Figure S20.** Expansion of ROESY spectrum of **16**, 1.0–5.0 ppm (600 MHz, $CDCl_3$).



**Figure S21.** Isolation scheme for lipid **18**. Red highlights indicate antimalarial activity.



**Figure S22.** $^{1}$H NMR spectrum of **18** (500 MHz, $CDCl_3$).



**Figure S23.** $^{13}C$ and DEPT NMR spectra of **18** (125 MHz, $CDCl_3$).



**Figure S24.** COSY spectrum of **18** (500 MHz, $CDCl_3$).



**Figure S25.** HSQC spectrum of **18** (500 MHz, $CDCl_3$).



**Figure S26.** HMBC spectrum of **18** (500 MHz, $CDCl_3$).